Voices
Kamal S. Saini: 3 Novel Concepts to Assign Lines of Therapy in Solid Tumors in a Uniform Manner
Kamal S. Saini/LinkedIn

Kamal S. Saini: 3 Novel Concepts to Assign Lines of Therapy in Solid Tumors in a Uniform Manner

Kamal S. Saini, Executive Medical Director and Head of European Oncology Team at Fortrea, shared a post on LinkedIn:

“Opus exegi – My life’s work is done! The ESMO EnLiST guidelines have been published! We introduce 3 novel concepts to assign lines of therapy (LoT) in solid tumors in a uniform manner:

  1.  All systemic therapies for invasive cancer should be assigned a line – not just in the advanced setting (aLoT), but also in early setting (eLoT). Therapies consisting of only investigational agent(s) are recorded separately (iLoT).
  2.  Distinction between a “New” LoT and a “Modified” LoT – If a change in systemic therapy results from clinical progression of disease (cPD) or lack of adequate tumour response, it is assigned a New LoT; and if the change results from intolerability (or financial or logistic reasons), it is assigned a Modified LoT.
  3.  X.Y format – LoT is recorded as two numerals separated by a decimal point. X refers to a New LoT and Y to a Modified LoT. Following LoT 1.0, the next New LoT will be LoT 2.0. Following LoT 1.0, the next Modified LoT will be LoT 1.1.

EnLiST provides a set of standard definitions, the format of reporting LoT, the minimum required data to be recorded, and guidelines for assigning LoT.

This work is an adaptation of our previous publication (Saini & Twelves. British Journal of Cancer. 2021; 125(2):155-163), and marks the successful culmination of 11 years of effort.

Now to pilot this in the real world – clinical trials, hospitals, EMRs, and RWD. Perhaps with the assistance of AI? We welcome your ideas and collaboration!

Opus exegi? Or are we just getting started?”

Title: ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours

Authors: K.S. Saini, M. Koopman, D. Martins-Branco, P. Bossi, S. Braendegaard Winther, M. Brahmi, I. Braña, E. Calvo, L. Castelo-Branco, I. Colombo, E. de Azambuja, D. De Ruysscher, R. Dienstmann, A-M.C. Dingemans, M. Ekholm, C. Gallois, V. Golfinopoulos, E. Grande, S. Halabi, E. Le Rhun, O. Le Saux, N.B. Leighl, S. Lonardi, S. Lorenzen, D. Lorusso, Giuseppe Minniti, G. Mountzios, J. Oldenburg, S.F. Oosting, P. Osterlund, J.L. Perez-Gracia, A. Pellat, S. Piperno-Neumann, R. Plummer, C. Porta, K. Punie, I. Ray-Coquard, J. Remon, C.H. Ruhlmann, P. Rutkowski, L.L. Siu, S. Stacchiotti, C. Suarez, K. Suijkerbuijk, J. Taieb, D. Trapani, A. Valachis, H.W.M. van Laarhoven, A. Vogel, A. Zer, G. Pentheroudakis, S. Delaloge, C. Twelves

Read the Full Article.

Kamal S. Saini: 3 Novel Concepts to Assign Lines of Therapy in Solid Tumors in a Uniform Manner

Other articles featuring Kamal S. Saini on OncoDaily.

A-M.C. Dingemans A. Pellat A. Valachis A. Vogel A. Zer C. Gallois C. Porta C. Suárez C. Twelves C.H. Ruhlmann cancer D. De Ruysscher D. Lorusso D. Martins Branco D. Trapani E. Calvo E. de Azambuja E. Grande E. Le Rhun EnLiST G Pentheroudakis G. Mountzios Giuseppe Minniti H.W.M. van Laarhoven I. Braña I. Colombo I. Ray-Coquard J. Oldenburg J. Remon J. Taieb J.L. Perez-Gracia K. Punie K. Suijkerbuijk K.S. Saini Kamal S. Saini L. Castelo-Branco L.L. Siu M. Brahmi M. Ekholm M. Koopman N.B. Leighl O. Le Saux OncoDaily Oncology P. Bossi P. Osterlund P. Rutkowski R. Dienstmann R. Plummer S. Braendegaard Winther S. Delaloge S. Halabi S. Lonardi S. Lorenzen S. Piperno-Neumann S. Stacchiotti S.F. Oosting V. Golfinopoulos